Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Peptide Vaccination in Combination With Either Ipilimumab or Vemurafenib for the Treatment of Patients With Unresectable Stage III or IV Malignant Melanoma A Phase I Study (First in Man)

NCT02077114 is registered in ClinicalTrials.gov with Herlev Hospital as lead sponsor.

NCT NCT02077114
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02077114 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Peptide Vaccination in Combination With Either Ipilimumab or Vemurafenib for the Treatment of Patients With Unresectable Stage III or IV Malignant Melanoma A Phase I Study (First in Man)
Lead sponsor
Herlev Hospital
Phase
Phase 1
Overall status
Completed
Start date
February 28, 2014
Completion date
Not reported
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malignant melanoma with metastasis